Atezolizumab plus personalized neoantigen vaccination in urothelial cancer: a phase 1 trial.

Saved in:
Bibliographic Details
Title: Atezolizumab plus personalized neoantigen vaccination in urothelial cancer: a phase 1 trial.
Authors: Saxena M; Vaccine and Cell Therapy Laboratory, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.; Department of Medicine, Division of Hematology Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Anker JF; Department of Medicine, Division of Hematology Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Kodysh J; Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA., O'Donnell T; Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Kaminska AM; Vaccine and Cell Therapy Laboratory, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Meseck M; Vaccine and Cell Therapy Laboratory, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Hapanowicz O; Department of Medicine, Division of Hematology Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Niglio SA; New York University Langone Laura and Isaac Perlmutter Cancer Center, New York, NY, USA., Salazar AM; Oncovir, Inc., Washington, D.C., USA., Shah HR; Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Kinoshita Y; Department of Pathology, Molecular, and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Brody R; Department of Pathology, Molecular, and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Rubinsteyn A; Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.; University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Sebra RP; Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Bhardwaj N; Vaccine and Cell Therapy Laboratory, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. nina.bhardwaj@mssm.edu.; Department of Medicine, Division of Hematology Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. nina.bhardwaj@mssm.edu.; Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. nina.bhardwaj@mssm.edu.; Parker Institute of Cancer Immunotherapy, San Francisco, CA, USA. nina.bhardwaj@mssm.edu., Galsky MD; Department of Medicine, Division of Hematology Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. matthew.galsky@mssm.edu.
Source: Nature cancer [Nat Cancer] 2025 Jun; Vol. 6 (6), pp. 988-999. Date of Electronic Publication: 2025 May 09.
Publication Type: Journal Article; Clinical Trial, Phase I
Journal Info: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101761119 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2662-1347 (Electronic) Linking ISSN: 26621347 NLM ISO Abbreviation: Nat Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2662-1347
DOI:10.1038/s43018-025-00966-7